Ropivacaine 0.2% for S-ESPB — Competitive Intelligence Brief

Ropivacaine 0.2% for S-ESPB (Ropivacaine 0.2% for S-ESPB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (amide). Area: Anesthesia.

marketed Local anesthetic (amide) Voltage-gated sodium channels Anesthesia Small molecule

Target snapshot

Ropivacaine 0.2% for S-ESPB (Ropivacaine 0.2% for S-ESPB) — Poznan University of Medical Sciences. Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ropivacaine 0.2% for S-ESPB TARGET	Ropivacaine 0.2% for S-ESPB	Poznan University of Medical Sciences	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Liposome bupivacaine	Liposome bupivacaine	Catherine Vandepitte, M.D.	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
IV lignocaine bolus and infusion	IV lignocaine bolus and infusion	University of Auckland, New Zealand	marketed	Local anesthetic; Class IB antiarrhythmic agent	Voltage-gated sodium channels
Levobupivacaine and Fentanyl	Levobupivacaine and Fentanyl	Hamad Medical Corporation	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels; mu-opioid receptor
Intravenous Lidocaine infusion + Standard Anesthesia	Intravenous Lidocaine infusion + Standard Anesthesia	Instituto Mexicano del Seguro Social	marketed	Local anesthetic (sodium channel blocker)	Voltage-gated sodium channels
Lidocaine plus adrenaline	Lidocaine plus adrenaline	University of Santiago de Compostela	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 and beta-1 adrenergic receptors
lidocaine with propofol	lidocaine with propofol	Imam Abdulrahman Bin Faisal University	marketed	Local anesthetic and sedative-hypnotic combination	Voltage-gated sodium channels (lidocaine); GABA-A receptors (propofol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (amide) class)

1. Poznan University of Medical Sciences · 4 drugs in this class
2. Nantes University Hospital · 3 drugs in this class
3. Bozyaka Training and Research Hospital · 2 drugs in this class
4. ASST Gaetano Pini-CTO · 2 drugs in this class
5. Centre Hospitalier Universitaire de Nīmes · 1 drug in this class
6. Chiang Mai University · 1 drug in this class
7. Beijing Tiantan Hospital · 1 drug in this class
8. Complejo Hospitalario Universitario de Granada · 1 drug in this class
9. Ciusss de L'Est de l'Île de Montréal · 1 drug in this class
10. China Medical University, China · 1 drug in this class